Drug Approval | January 13, 2022
South Korea approves Novavax Covid-19 vaccine
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
The last date to apply for this program is 18th January 2022
ICICI Direct gives a preview on the earnings narrative for Q3FY22
This test analyses samples in VTM directly without the need for RNA extraction step
Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer
The product will be marketed under store brand labels and is comparable to the brand Zyrtec
This surpasses the number of approvals supported in 2020
MultiTEP Platform-based vaccine targeting three B cell epitopes of pathological ?-Synuclein simultaneously shows protective efficacy in mouse model of synucleinopathies
This service benefits pharmaceutical and fine chemical companies looking to optimise their reactions
The study will be published on the pre-print server, medRXiv, shortly
Subscribe To Our Newsletter & Stay Updated
